Virica Biotech: Funding, Investors & Team (Sep 2026)
Cell and gene therapies, as well as viral vaccines, need higher production yields—and that's where we excel. We significantly increase yields by targeting the innate cellular defenses within production cells. These natural defenses, designed to combat foreign genetic material and inhibit viral replication, can hinder your process. Our solution is a unique panel small molecules which make up our Viral Sensitizer (VSETM) platform, which dampen cellular defenses. Using an innovative high-throughput screening process, we have developed a library of novel VSEs. Virica continues to leverage this advanced technology to pinpoint the most synergistic Viral Sensitizer molecules from our library, tailored to any virus or cell line. We customize formulations of these Viral Sensitizers to enhance virus yield in your manufacturing process or optimize the effectiveness of your viral therapies. The result is higher yields and improved quality, helping to reduce costs and improve patient access.
Virica Biotech has raised $5.2M across 5 funding rounds on record, the most recent an undisclosed round announced in Oct 2024.
Virica Biotech Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Virica Biotech Funding Rounds
1 of 5 rounds was announced without a disclosed amount and is excluded from the total.
Virica Biotech raised $500k in an undisclosed round announced in Jun 2022.
10 months later, an undisclosed round of $580k was announced in Apr 2023.
9 months later, an undisclosed round of $3.0M was announced in Jan 2024.
5 months later, an undisclosed round of $1.1M was announced in Jun 2024.
4 months later, an undisclosed round was announced in Oct 2024 with no disclosed amount.
Virica Biotech Founders and Leadership Team
No contact details are on record for this team yet.
Virica Biotech Funding Compared to Other Biotechnology Startups
Funded Startups Like Virica Biotech in Biotechnology and Ottawa
Companies Similar to Virica Biotech
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Virica Biotech Funding FAQs
What does Virica Biotech do?
Cell and gene therapies, as well as viral vaccines, need higher production yields—and that's where we excel. We significantly increase yields by targeting the innate cellular defenses within production cells. These natural defenses, designed to combat foreign genetic material and inhibit viral replication, can hinder your process. Our solution is a unique panel small molecules which make up our Viral Sensitizer (VSETM) platform, which dampen cellular defenses. Using an innovative high-throughput screening process, we have developed a library of novel VSEs. Virica continues to leverage this advanced technology to pinpoint the most synergistic Viral Sensitizer molecules from our library, tailored to any virus or cell line. We customize formulations of these Viral Sensitizers to enhance virus yield in your manufacturing process or optimize the effectiveness of your viral therapies. The result is higher yields and improved quality, helping to reduce costs and improve patient access.
How much funding has Virica Biotech raised?
Virica Biotech has raised $5.2M across 5 rounds on record.
When did Virica Biotech last raise funding?
Virica Biotech's most recent funding round on record was announced in Oct 2024. The amount was not disclosed.
Who founded Virica Biotech?
FundedIQ lists Jean Simon Diallo (Founder) at Virica Biotech.
Where is Virica Biotech headquartered?
Virica Biotech is based in Ottawa, Ontario, Canada.
How many employees does Virica Biotech have?
Virica Biotech is in the 11-50 employee band.
About FundedIQ's Virica Biotech Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Virica Biotech is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.